Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

Table 2 RAPID3, RADAI-TS, and RADAI-JS effect sizes and relative efficiency between baseline and week 12 in CZP-treated patients

	Effect size at week 12	Relative efficiency^a vs. DAS28(CRP) at week 12
RAPID3	−1.02	0.27
RADAI-TS	−1.10	0.32
RADAI-JS	−0.78	0.16
Baseline RADAI-JS^b
0–4 joints	–	0.11
5–8 joints	–	0.71
9–12 joints	–	1.60
13–16 joints	–	1.75

CRP C-reactive protein, CZP certolizumab pegol, DAS28 Disease Activity Score in 28 joints, RADAI Rheumatoid Arthritis Disease Activity Index, RAPID3 Routine Assessment of Patient Index Data 3, JS joint score, TS total score
^aValue of 1 indicates equivalent efficiency
^bBy number of affected joints at baseline

ISSN: 1478-6362